BR112023021868A2 - Tratamento de lúpus eritematoso cutâneo - Google Patents

Tratamento de lúpus eritematoso cutâneo

Info

Publication number
BR112023021868A2
BR112023021868A2 BR112023021868A BR112023021868A BR112023021868A2 BR 112023021868 A2 BR112023021868 A2 BR 112023021868A2 BR 112023021868 A BR112023021868 A BR 112023021868A BR 112023021868 A BR112023021868 A BR 112023021868A BR 112023021868 A2 BR112023021868 A2 BR 112023021868A2
Authority
BR
Brazil
Prior art keywords
lupus erythematosus
cutaneous lupus
treatment
methods
relates
Prior art date
Application number
BR112023021868A
Other languages
English (en)
Inventor
Catharina Lindholm
Joachim Almquist
Joan Merrill
Katie Streicher
Lorin Roskos
Rajendra Tummala
Tomas Rouse
Victoria Werth
Lin Chia Yen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112023021868A2 publication Critical patent/BR112023021868A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

tratamento de lúpus eritematoso cutâneo. a presente invenção refere-se a métodos e composições para o tratamento de lúpus eritematoso cutâneo (lec). especificamente, a presente invenção refere-se a métodos que compreendem administrar a um indivíduo um inibidor do receptor de ifn tipo i.
BR112023021868A 2021-04-23 2022-04-22 Tratamento de lúpus eritematoso cutâneo BR112023021868A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163178750P 2021-04-23 2021-04-23
PCT/EP2022/060669 WO2022223770A1 (en) 2021-04-23 2022-04-22 Treatment of cutaneous lupus erythematous

Publications (1)

Publication Number Publication Date
BR112023021868A2 true BR112023021868A2 (pt) 2023-12-19

Family

ID=81850041

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021868A BR112023021868A2 (pt) 2021-04-23 2022-04-22 Tratamento de lúpus eritematoso cutâneo

Country Status (9)

Country Link
EP (1) EP4326322A1 (pt)
KR (1) KR20240000557A (pt)
CN (1) CN117222430A (pt)
AU (1) AU2022261422A1 (pt)
BR (1) BR112023021868A2 (pt)
CA (1) CA3216390A1 (pt)
IL (1) IL307750A (pt)
TW (1) TW202317617A (pt)
WO (1) WO2022223770A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2662390T3 (da) * 2004-06-21 2017-11-06 Squibb & Sons Llc Interferon alpha receptor 1-antistoffer og anvendelse heraf
JP5608100B2 (ja) 2008-02-08 2014-10-15 メディミューン，エルエルシー 低下したＦｃリガンド親和性を有する抗ＩＦＮＡＲ１抗体
PT2473636T (pt) 2009-09-03 2017-02-06 Medimmune Llc Diagnóstico de interferão de tipo-1
ES2818229T3 (es) * 2015-08-19 2021-04-09 Astrazeneca Ab Formulación anti-IFNAR1 estable
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用

Also Published As

Publication number Publication date
AU2022261422A9 (en) 2023-12-07
EP4326322A1 (en) 2024-02-28
WO2022223770A1 (en) 2022-10-27
CA3216390A1 (en) 2022-10-27
CN117222430A (zh) 2023-12-12
AU2022261422A1 (en) 2023-11-30
TW202317617A (zh) 2023-05-01
KR20240000557A (ko) 2024-01-02
IL307750A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
CO2021005987A2 (es) Compuestos de anillo fusionado
CL2021000382A1 (es) Compuestos novedosos de sulfonamidaurea
CL2021000387A1 (es) Compuestos de anillo fusionado
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
BR112017024773A2 (pt) compostos depsipeptídeos anti-helmínticos
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
CL2020003008A1 (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CO2022000481A2 (es) Inhibidores de enzimas
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
BR112023014973A2 (pt) Derivados de urolitina e métodos de uso dos mesmos
CO2022000270A2 (es) Inhibidores de enzimas
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2022000266A2 (es) Inhibidores de enzimas
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
BR112023017367A2 (pt) Composições e métodos para inibição de ceto-hexoquinase (khk)
BR112021024109A2 (pt) Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
EA201270192A1 (ru) Композиции и способы применения для пострадиационной защиты
BR112017015744A2 (pt) composto apresentando uma estrutura de fórmula (i), um sal farmaceuticamente aceitável do mesmo ou um isômero ótico do mesmo, composição farmacêutica e uso do composto de fórmula (i) para o tratamento e prevenção de mycobacterium tuberculosis ou outras infecções microbianas